Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.05 - $5.43 $202,905 - $272,043
-50,100 Reduced 28.99%
122,700 $640,000
Q1 2024

May 15, 2024

BUY
$3.25 - $5.27 $475,475 - $771,000
146,300 Added 552.08%
172,800 $782,000
Q4 2023

Feb 14, 2024

SELL
$3.34 - $4.29 $217,100 - $278,850
-65,000 Reduced 71.04%
26,500 $96,000
Q3 2023

Nov 15, 2023

BUY
$3.91 - $5.45 $357,765 - $498,675
91,500 New
91,500 $377,000

Others Institutions Holding MNKD

About MANNKIND CORP


  • Ticker MNKD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 257,338,000
  • Market Cap $1.6B
  • Description
  • MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...
More about MNKD
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.